New Antibody-Chemo cocktail shows promise for tough lung cancers
NCT ID NCT05215067
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested a new drug called AK104 (a bispecific antibody that targets two immune checkpoints) combined with the chemotherapy docetaxel in 44 adults with advanced non-small cell lung cancer whose disease had progressed after platinum-based chemotherapy and an anti-PD-1/PD-L1 drug. The study aimed to see if the combination could shrink tumors and control the disease longer. Results are not yet reported, but the approach tries to boost the immune system while directly killing cancer cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AK104 (a bispecific antibody targeting PD-1 and CTLA-4) combined with docetaxel chemotherapy
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced lung cancer whose disease has worsened after standard therapies.
- What could go wrong
- This is a small, early-phase trial (44 people) with no control group, so results may not be definitive. Side effects from combining immunotherapy and chemotherapy can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangsu Cancer Hospital
Nanjing, Jiangsu, 210009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill outperform chemo for a Hard-to-Treat lung cancer mutation?
- Can a Triple-Drug combo outsmart Immunotherapy-Resistant lung cancer?
- Which palliative care approach boosts quality of life in advanced lung cancer?
- Experimental drug combo targets Hard-to-Treat lung cancer
- Can a smartphone app ease the burden of advanced lung cancer?
- Breath of discovery: simple test may sniff out lung cancer